Simvastatin Myopathy Rate Spells Trouble For High Doses In “A to Z” Trial
This article was originally published in The Tan Sheet
Executive Summary
An increased rate of myopathy in study participants taking an 80 mg dose of Merck's Zocor (simvastatin) suggests that high doses of the drug "should be used with caution," according to an editorial slated for publication in the Sept. 15 Journal of the American Medical Association
You may also be interested in...
J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group
J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD
Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins
Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: